INNOVATING targeting
INNOVATING targeting
Philogen is a Swiss-Italian integrated biotechnology company founded in 1996, with the mission to develop innovative biopharmaceuticals for the treatment of angiogenesis-related disorders. Angiogenesis, i.e. the formation ... Read all
Philogen announces the completion of a second interim analysis of its phase III clinical program with NidlegyTM for the treatment of melanoma
Read allPhilogen is a fully integrated company active in the discovery, GMP production and clinical development of targeted therapeutics. We have a leading position in the field of antibody-based therapeutics ... Read all
Philogen has finalized numerous collaborative agreements with large pharmaceutical companies. Read all
